RECEIVED CENTRAL FAX CENTER





Theravance

Facsimile Cover Sheet

To:

Commissioner for Patents

U. S. Patent and Trademark Office

Fax:

(703) 872-9306

From:

Roberta P. Saxon, Ph. D.

Reg. No. 43,087

Patent Department

Company: Telephone:

Theravance, Inc.

T erebnor

650-808-3764

Fax:

650-808-6078

Date:

August 9, 2004

of pages:

4 (including this page)

Re: Supplemental Information Disclosure Statement

U. S. Serial Number 10/627,555

Attorney Docket No: P-154-US1

Examiner: Shailendra Kumar

Group Art Unit: 1621

Attached are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages)
- 2. Information Disclosure Statement by Applicant (Form PTO/SB/08a) 1 page

Certificate of Facsimile Transmission

<u>Facsimile Number: (703) 872-9306</u>			
I hereby certify that this correspondence is being transmitt	ted on the d	ate shown below via facsimile	to Commissioner for
Patents, United States Patent and Trademark Office at the	facsimile n	umber indicated above.	<u>:</u>
By: Barbara Bryant	_ Date: _	August 9, 2004	
Notice of Confidentiality			1
The following transmittal contains confidential	informat	ion intended exclusively	for the above-named
person. Use, copying, distribution or disclosure			
Disease and The reviewed Two of the chore number	oi intoi ka	ero magained this fay in an	ror and withor dostroy
Please call Theravance, Inc. at the above number	r ii you na	ve received this lax in el	ior, and ender destroy
or return the enclosures to us.			
و و برون پر پر پر بر مند تا آن اگر ان هم معروب پر پر پر پر پر برای این برای در برای در برای در برای در برای در			
, , , , , , , , , , , , , , , , , , ,			:

901 Gateway Blvd., South San Francisco, CA 94080; Tel. (650) 808-6000; Fax (650) 808-6078

PRIVILEGED AND CONFIDENTIAL

CENTRAL FAX CENTER

AUG 0 9 2004

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted v Patents, United States Patent and Trademark Office, on the dat By: Barbara Bryant	ia facsimile number (703) 872-9306 to Commissioner for c shown below: Date: 4 2004
Barbara Bryant	Patent
	Attorney's Docket No. P-154-US1
IN THE UNITED STATES PATEN	T AND TRADEMARK OFFICE
In re Patent Application of)
MORAN et al.) Group Art Unit: 1621
Application No.: 10/627,555	Examiner: Shailendra Kumar
Filed: July 25, 2003	j
For: CRYSTALLINE B ₂ ADRENERGIC RECEPTOR AGONIST)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 CFR §1.56, Applicants hereby submit the following information in conformance with CFR §§1.97 and 1.98. Enclosed herewith is form PTO/SB/08a which lists a document for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Attorney Docket No. P-154-US1 Application Serial No.: 10/627,555 Page 1 of 2

A copy of the U.S. patent cited on the accompanying PTO Form PTO/SB/08a has been omitted in accordance with the notice published August 5, 2003 in the Official Gazette 55, stating that the requirement under 37 CFR 1.98 (a)(2) for submitting such copies has been waived for U.S. national patent applications filed after June 30, 2003.

Consideration of the listed document is respectfully requested. Additionally, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO/SB/08a to Applicants.

This Information Disclosure Statement is being filed before the mailing date of a first official action on the merits for this application and therefore, no fee or certification is required under 37 CFR §1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees under 37 CFR §1.97(c) for submission of this paper to Deposit Account No. 50-0344.

Should there be any questions concerning the cited document, the Examiner is encouraged to telephone the undersigned agent for Applicants at (650) 808-3764 (direct).

Respectfully submitted,

THERAVANCE, INC.

Date: August 9, 2004

r. Douca VI

Roberta P. Saxon, Ph.D. Registration No. 43,087

THERAVANCE, INC. 901 Gateway Boulevard South San Francisco, CA 94080

Tel: (650) 808-6000 Fax: (650) 808-6078

PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ite for form 144	9A/PTO			Complete if Known	
				Application Number	10/627,555	
INF	ORMATI	ION DIS	CLOSURE	Filing Date	July 25, 2003	
STA	TEMEN	T BY A	PPLICANT	First Named Inventor	Martin S. LINSELL	
				Art Unit	1621	
	(Use as ma	any sheets as	necessary)	Examiner Name	Shallendra Kumar	
Sheet	1	of	1	Attorney Docket Number	P-154-US1	

U.S. PATENT DOCUMENTS						
Examiner C Initials * N	Cite	Document Number	Document Number Publication Date		Pages, Columns, Lines, Where Releva	
	Cite No.	Number - Kind Code ² (# known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
	_A1	US-6,683,115 B2	01-27-04	Moran et al.		
		US-				
		US-			,	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	T	US-				
		US-				
		US-				
		US-				
	T	US-				
		US-		/		
	<u> </u>	US-		1		

		FOREIGN PA	TENT DOCU	MENTS	,	:
	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁶ (# known)				T ⁰
<u> </u>						
	<u> </u>				<u> </u>	
			```			
	<b></b>					
	<b> </b>					ļ
	<u> </u>					

Examiner Signature	Date Considered	:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kintis Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to piece a check mark here if English renigueage Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2